VBI-2601
- Generic Name
- VBI-2601
A Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and PEG-IFNα in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE)
Phase 2
Active, not recruiting
- Conditions
- Chronic Hepatitis B Virus (HBV) Infection
- Interventions
- Drug: BRII-835 (VIR-2218)Drug: Placebo of BRII-179Biological: PEG-IFNαDrug: Placebo of BRII-835
- First Posted Date
- 2024-10-21
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- Brii Biosciences Limited
- Target Recruit Count
- 180
- Registration Number
- NCT06650852
- Locations
- 🇨🇳
Investigative Site 86002, Guangzhou, Guangdong, China
🇨🇳Investigative Site 86006, Shanghai, Shanghai, China
🇨🇳Investigative Site 86007, Shanghai, Shanghai, China
Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH)
Phase 2
Active, not recruiting
- Conditions
- For Treatment of Chronic Hepatitis B Virus Infection
- Interventions
- First Posted Date
- 2024-07-09
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- Brii Biosciences Limited
- Target Recruit Count
- 150
- Registration Number
- NCT06491563
- Locations
- 🇨🇳
Investigative Site 86004, Beijing, Beijing, China
🇨🇳Investigative Site 86009, Beijing, Beijing, China
🇨🇳Investigative Site 86015, Xiamen, Fujian, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath